Kuzin, Maxim
Schoretsanitis, Georgios
Haen, Ekkehard
Stegmann, Benedikt
Hiemke, Christoph
Gründer, Gerhard
Paulzen, Michael http://orcid.org/0000-0003-4198-5160
Article History
First Online: 2 September 2017
Compliance with ethical standards
:
: Ekkehard Haen received speaker’s or consultancy fees from the following pharmaceutical companies: Servier, Novartis, and Janssen-Cilag. He is managing director of AGATE, a non-profit working group to improve drug safety and efficacy in the treatment of psychiatric diseases. He reports no conflicts of interest with this publication. Christoph Hiemke has received speaker’s or consultancy fees from Janssen-Cilag and Servier. He is managing director of psiac GmbH, which provides an internet-based DDI program for psychopharmacotherapy. He reports no conflicts of interest with this publication. Gerhard Gründer has served as a consultant for Boehringer Ingelheim (Ingelheim, Germany), Eli Lilly (Indianapolis, IN, USA), Lundbeck (Copenhagen, Denmark), Ono Pharmaceuticals (Osaka, Japan), Roche (Basel, Switzerland), Servier (Paris, France), and Takeda (Osaka, Japan). He has served on the speakers’ bureau of Eli Lilly, Gedeon Richter (Budapest, Hungary), Janssen Cilag (Neuss, Germany), Lundbeck, Roche, Servier, and Trommsdorf (Aachen, Germany), and has received grant support from Boehringer Ingelheim and Roche. He is co-founder of Pharma Image GmbH (Düsseldorf, Germany) and Brainfoods GmbH (Selfkant, Germany). He reports no conflicts of interest with this publication. Georgios Schoretsanitis received a grant from the bequest ‘in memory of Maria Zaoussi’, State Scholarships Foundation, Greece, for clinical research in psychiatry for the academic year 2015–2016. Maxim Kuzin, Benedikt Stegmann, Michael Paulzen declare no conflicts of interest.
: The research study did not receive funds or support from any source.